Enhance patient safety and study quality by using data, analytics, and technology to monitor patient, site, and study performance with risk-based and centralized monitoring.
As the global healthcare industry diligently worked to diminish the impact of the pandemic worldwide, many pharmaceutical companies accelerated research for COVID-19 vaccines. It was key for every component of clinical development to work with efficiency, collaboration, innovation and experience, given the time sensitivities around the need for effective vaccines viable options.
A global pharmaceutical company realized that their initial narrative vendor could not deliver the growing volume of narratives within the planned timelines. Also working with multiple functions and units across the full enterprise to rapidly develop a COVID-19 vaccine for potential emergency use authorization (EUA), the company selected the IQVIA Medical Writing team to oversee their development and delivery for an interim analysis. The IQVIA Medical Writing team quickly initiated the work and successfully delivered all requested text narratives (>1,000) in the short time span of four weeks and ahead of schedule, leveraging innovative tech-enabled processing solutions combined with medical writing narrative expertise.
Enhance patient safety and study quality by using data, analytics, and technology to monitor patient, site, and study performance with risk-based and centralized monitoring.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.